جست‌وجوی استاد و پژوهشگر

Sudie E. Backمشاهده پروفایل

استاد

• Substance Use Disorders
• Post-Traumatic Stress Disorder (PTSD)
• Co-occurring Disorders
• +۳ مورد دیگر

Dr. Sudie E. Back is a Professor in the Department of Psychiatry and Behavioral Sciences at the Medical University of South Carolina (MUSC), College of Medicine. She also serves as Director of the NIH-sponsored Drug Abuse Research Training (DART) program and is a Staff Psychologist at the Ralph H. Johnson VA's STAR program. Her expertise lies in treating substance use disorders and PTSD, particularly among veterans and civilians. She leads both behavioral and pharmacological clinical trials, as well as neuroimaging studies. Education: PhD in Clinical Psychology from the University of Georgia (2004), clinical internship at Yale University School of Medicine (2002–2003), and postdoctoral training at MUSC (2004–2005). Research Interests: Co-occurring substance use and PTSD, trauma-focused therapies, veterans' mental health. Funding: NIH, Department of Defense, and VA grants, including K23, R01, K02, and a Fulbright award. Dr. Back has pioneered integrated treatment approaches, such as combining oxytocin with exposure therapy for AUD and PTSD. She also developed COPEWeb , a web-based training program for providers treating PTSD and SUD. Her trials include randomized clinical trials on cognitive processing therapy and relapse prevention. Awards: Career Development Award (K23) R01 grants Independent Scientist Award (K02) Fulbright Scholar Award (Australia) Labs/Teams: Director of DART program at MUSC and STAR program at the VA, focusing on translational research and clinical training.

Kora DeBeckمشاهده پروفایل

استاد

• Substance Use
• Drug Policy
• Health Policy
• +۳ مورد دیگر

Kora DeBeck is a Distinguished Professor of Substance Use and Drug Policy in the School of Public Policy at Simon Fraser University, a CIHR Applied Public Health Chair, and Dorothy Killam Fellow. She is also a Research Scientist with the BC Centre on Substance Use and Principal Investigator of the At-Risk Youth Study (ARYS), a longitudinal cohort tracking over 1,200 street-involved youth. Her research focuses on substance use policy, health services for marginalized populations, and the structural drivers of drug-related harms. She has published over 200 peer-reviewed articles challenging ineffective drug enforcement models and advocating for policy reforms. Recent publications analyze trends in opioid use, harm reduction during the COVID-19 pandemic, drug decriminalization, and youth-focused interventions. Her work consistently addresses social inequities through data-driven approaches to the toxic drug crisis. CIHR Applied Public Health Chair Dorothy Killam Fellow Michael Smith Health Research BC Scholar Award Distinguished SFU Professorship She has secured over $50 million in research funding, including $21M as principal investigator for ARYS. Her lab collaborates with healthcare providers, community organizations, and policymakers to translate research into practice.

• Tobacco Cessation
• Health Policy
• Health Insurance Benefit Mandates
• +۳ مورد دیگر

Dr. Sara McMenamin is an Associate Professor at the Herbert Wertheim School of Public Health & Human Longevity Science at UC San Diego. She serves as the Associate Director of the MPH program and Interim Assistant Dean for Undergraduate Education . Her research focuses on state-level policies addressing tobacco use and preventive services, particularly health insurance coverage for tobacco dependence treatment in California and nationally. She also co-chairs the California Health Benefits Review Program , evaluating proposed health insurance legislation's medical, cost, and public health impacts. Her work spans public health policy analysis , health insurance mandate evaluations, and tobacco control strategies. Key areas include analyzing the effects of tobacco tax increases (e.g., Proposition 56), tracking smoking trends among youth and adults, and investigating the interplay between e-cigarette use and smoking cessation. She has contributed to studies on fertility preservation mandates, telemedicine for substance use disorders, and health equity in insurance access. Recent research highlights include assessing declines in youth smoking despite e-cigarette surges, evaluating tobacco policy coverage changes in California, and projecting future cigarette consumption trends. Her work often bridges policy implementation and population health outcomes, emphasizing evidence-based approaches. Dr. McMenamin collaborates with interdisciplinary teams and state agencies to translate research into actionable policies. Her contributions span over 150 peer-reviewed publications, with frequent media and policy engagement (e.g., cited in 14+ news outlets for key studies).

Benjamin Drussمشاهده پروفایل

استاد

• Mental Health
• Health Policy
• Public Health
• +۳ مورد دیگر

Benjamin Druss is a Professor and Rosalynn Carter Chair in Mental Health at Emory University’s Rollins School of Public Health, Department of Health Policy and Management. He is a psychiatrist integrating mental health, physical health, and public health. His research focuses on improving care access/outcomes for populations with serious mental illnesses and medical comorbidities. He serves on JAMA Psychiatry’s editorial board and previously on NIMH’s National Advisory Council. Education: MD, New York University MPH, Yale University Research Interests: Health policy for mental health systems Social determinants of mental health Psychosis and comorbidity mechanisms Healthcare access disparities Articles Trends: Recent work examines opioid use patterns, mental health policy impacts, and neighborhood effects on psychiatric outcomes. Over 15 years of publications consistently address disparities in mental health care access and systemic solutions. Awards: APA Health Services Research Senior Scholar Award Carl Taube Award for Lifetime Contribution NAMI Exemplary Psychiatrist Award Advising/Grants: Leads research on mental health workforce resilience and Medicaid policy. Courses taught include mental health/medical policy, public mental health case studies, and dissertation guidance.

David Lydon-Staleyمشاهده پروفایل

دانشیار

• Health Communication
• Substance Use
• Media Effects
• +۷ مورد دیگر

David Lydon-Staley is an Associate Professor at the Annenberg School for Communication, University of Pennsylvania, where he serves as Principal Investigator of the Addiction, Health, & Adolescence (AHA!) Lab. His research integrates neuroscience with communication science to examine substance use, media effects, and curiosity using fMRI, ecological momentary assessment, and network analysis. Education includes a Ph.D. in Human Development & Family Studies from The Pennsylvania State University, an M.S. from Penn State, an M.F.A. in Creative Writing from Drexel University (2025), and a B.A. in Psychology and English Literature from Trinity College Dublin. Research focuses on three interconnected areas: curiosity in media environments and health communication, media engagement in emotion dynamics, and substance use through dynamic network perspectives. Work emphasizes intensive longitudinal measurement of brain-behavior interactions during daily life. Recent publications (2023-2025) predominantly explore tobacco behavior, neural mechanisms of addiction, curiosity modulation, and social media's emotional impacts. Articles demonstrate consistent themes: fMRI analysis of inhibitory control, real-time geospatial tracking of smoking triggers, curiosity-based health messaging, and emotion regulation networks. Research has been supported by the National Institute on Drug Abuse, Jacobs Foundation, International Society for Behavioral Development, Center for Curiosity, and Brain & Behavior Research Foundation. Leads the Addiction, Health, & Adolescence (AHA!) Lab investigating substance use through network science approaches. Collaborates with the Complex Systems Lab at Penn's Department of Bioengineering.

• Pain Management
• Opioid Therapy
• Substance Abuse
• +۳ مورد دیگر

Maryam Kazemitabar is an Associate Research Scientist in the Department of Internal Medicine at Yale University's School of Medicine. She holds a Ph.D. in Psychometrics from the University of Tehran (2020). Her work bridges research and clinical practice to improve patient outcomes in pain management, opioid therapy, and substance abuse. She collaborates with multidisciplinary teams to develop evidence-based interventions, leveraging her expertise in psychometric evaluation. Education: Ph.D. in Psychometrics (Measurement and Evaluation), University of Tehran, 2020 Research Interests: Pain management strategies and opioid-related risks Substance use disorders and comorbid mental health conditions Psychometric validation of health assessment tools Health equity in marginalized populations Research Trends: Recent work focuses on opioid overdose epidemiology, disparities in healthcare for migrant populations, and psychometric rigor in cross-cultural mental health measurement. Key methodologies include latent class analysis, scale validation, and mixed-methods approaches. Advising & Grants: While specific grants are not listed, her collaborative projects imply institutional and federal funding support. No formal advisees are documented here.

R. Lorraine Collinsمشاهده پروفایل

استاد

• Addictive Behaviors
• Substance Abuse Prevention
• Ecological Momentary Assessment
• +۳ مورد دیگر

R. Lorraine Collins, PhD, is a Professor in the Department of Community Health and Health Behavior and the Associate Dean for Research at the University at Buffalo’s School of Public Health and Health Professions (SPHHP). Her research focuses on cognitive and behavioral approaches to addictive behaviors, particularly among emerging and young adults. She is a leading expert in drinking restraint theory and has pioneered methodologies like ecological momentary assessment using cell phones for real-time data collection. Collins holds a PhD and has been affiliated with UB’s Research Institute on Addictions (RIA) since 1998. Her work emphasizes translational research with direct community impact, aiming to inform prevention and treatment programs for substance use disorders. Key contributions include developing the Temptation and Restraint Inventory (TRI), the Daily Drinking Questionnaire (DDQ), and the self-administered Timeline Follow-Back (S-TLFB) procedure. Collaborations span multiple disciplines, including pediatrics and biomedical sciences, reflecting her commitment to interdisciplinary solutions. Her NIH-funded research explores physical activity and marijuana use, leveraging expertise from diverse departments. Collins advocates for evidence-based interventions to address substance abuse across populations, emphasizing the societal relevance of her work in Western New York and beyond. Her awards and recognitions are tied to her contributions to addiction science, though specific prizes are not listed in the text. Her research has been widely cited in academic journals across psychology, public health, and behavioral medicine.

Rob Leyمشاهده پروفایل

استاد مدعو

• Public Art
• Architectural Design
• Urban Design
• +۳ مورد دیگر

Rob Ley is an Adjunct Professor at the USC School of Architecture, specializing in experimental architectural design and public art. He founded Rob Ley Studio, known for installations at venues like the Storefront for Art and Architecture (New York) and the Taubman Museum of Art. His work spans public commissions for institutions such as Eskenazi Hospital and O’Hare Airport. Ley holds a B.Arch from the University of Illinois and an M.Arch from UCLA. Education: Bachelor of Science in Architecture, University of Illinois, Urbana-Champaign (1993–1996) Master of Architecture, University of California, Los Angeles (1997–2000) Ley’s research focuses on integrating technology and innovation into public spaces, with a secondary emphasis on the social impact of design. His studio’s projects highlight experimental approaches to urban environments and community engagement. Awards & Grants: 2015 American’s for the Arts - Public Art Network Year in Review Award Graham Foundation Grant AIA Research Grants IDEC Special Projects Grant 2010 Best Storefront Design Award (Municipal Art Society of New York) Ley teaches graduate and undergraduate design studios at USC, emphasizing digital fabrication and materials innovation. He has lectured globally on public art and design at institutions such as Cooper Union and the American Institute Vienna. His work bridges architectural practice with social responsibility, advocating for design solutions that address urban challenges.

• Substance Use and Addiction
• HIV/AIDS Prevention
• Viral Hepatitis Transmission
• +۵ مورد دیگر

Robert Heimer is a Professor of Epidemiology (Microbial Diseases) and Pharmacology at Yale University, with affiliations to the Yale School of Public Health , Center for Interdisciplinary Research on AIDS (CIRA) , and Yale Institute for Global Health . His research focuses on substance use epidemiology , HIV and viral hepatitis prevention , and harm reduction strategies , particularly addressing the opioid crisis through interdisciplinary methods combining laboratory, behavioral, and structural analyses. PhD in Molecular Biology/Pharmacology (Yale University, 1988) BA in Molecular Biology (Columbia College, 1974) His work examines injection drug use consequences , syringe exchange programs , overdose prevention , and pharmacological addiction treatment , with funding from NIH, CDC, and Gilead Foundation. Recent publications analyze spatial overdose patterns , opioid treatment accessibility , and structural stigma in rural healthcare . He has contributed to understanding HIV transmission in Russia and global harm reduction policy . Scientific Awards: Recognized through Annual Research Awards and Career Achievement Awards at Yale School of Public Health. Dr. Heimer directs the Interdisciplinary Research Methods Core at CIRA and conducts fieldwork in Vietnam and Lebanon, addressing cross-border substance use challenges and stigma in marginalized populations . His research informs public health policy and prison-to-community healthcare transitions .

Stella Reskoمشاهده پروفایل

استاد

• Substance Use and Addiction
• Violence Prevention
• Public Health Policy
• +۲ مورد دیگر

Stella Resko is a Professor jointly appointed in the School of Social Work and the Merrill Palmer Skillman Institute for Child and Family Development at Wayne State University. She serves as Director of the social work doctoral program and the graduate certificate in alcohol and drug use studies (CADUS), with research focused on preventing substance use and violence through drug overdose prevention, treatment, and recovery initiatives. Dr. Resko's educational background includes: Post-Doctoral Fellow, University of Michigan Addiction Research Center Ph.D. in Social Work, Ohio State University M.S.W., Ohio State University B.S.S.W., Ohio State University Her research expertise spans substance use treatment and prevention, interpersonal violence, and public perceptions of cannabis and opioids, with emphasis on families affected by substance misuse and cannabis legalization impacts. Methodologically, she specializes in community-based research, advanced quantitative methods (latent variable and multilevel models), and survey design targeting adolescents, emerging adults, women, and families. Analysis of her recent publications reveals dominant themes in the opioid crisis, cannabis policy, and collegiate recovery programs, with consistent examination of stigma, public attitudes, and barriers to treatment across diverse populations including bereaved families and peer recovery specialists. Dr. Resko has received the following scientific recognition: Fellow of the Society for Social Work & Research As Director of the Social Work PhD program and CADUS certificate, she mentors doctoral students while serving as Co-Principal Investigator for Michigan's State Opioid Response grants evaluation, focusing on community-based interventions and policy implementation in substance use treatment. Her work is conducted through the Merrill Palmer Skillman Institute for Child and Family Development, involving collaboration with community treatment programs like Maryhaven and interdisciplinary research teams developing brief interventions for substance use prevention.

• Clinical Psychology
• Cognitive Behavioral Therapy
• Stress Management
• +۵ مورد دیگر

Hironori Shimada is Professor at Waseda University’s Faculty of Human Sciences and a member of the Science Council of Japan. Holding a Ph.D. from Waseda, he has served continuously on the faculties of Waseda, Niigata and Hiroshima Universities since 1996, specialising in clinical psychology, cognitive-behavioural therapy, stress management and public-health education. Education: 1996 – Ph.D. in Health Sciences, Graduate School of Human Sciences, Waseda University Research interests: Shimada’s work integrates cognitive-behavioural models with public-health approaches to develop and validate interventions for stress, anxiety, addiction, sexual offending, gambling disorder, and childhood behavioural problems. He investigates mechanisms such as cognitive fusion, self-compassion, and contingency perception, and translates findings into scalable manuals, smartphone apps, and school-based programmes. Recent articles (2024-2025) reveal concentrated effort on: Forensic CBT (sex-offender and adolescent-delinquency programmes), Addiction CBT (gambling, internet-gaming, kleptomania) utilising ACT and mindfulness components, Stress-management education in schools and workplaces (self-compassion, help-seeking, teacher mental-health), Psychometric development (Japanese versions of IORNS, cognitive-fusion scales, gambling-urge scales). Scientific awards: JSSM Awards 2018 JAHP Awards 2018 JABCT Awards 2017 Japan Society for Stress Management Award (joint) 2017 JABT Awards 2006 & 2004 JACS Awards 2001 JSBM Awards 2001 JSPM & JAHP Awards 1997 Advising & grants: While individual student names are not listed, Shimada leads large-scale school-based intervention trials and forensic treatment projects implying substantial graduate supervision; funding sources are implied through continuous institutional and ministerial committee appointments. Labs & teams: He heads clinical-psychology laboratories within Waseda’s Faculty of Human Sciences, coordinating multi-site projects on CBT dissemination, stress-management scale development, and forensic risk assessment, while collaborating with correctional and educational authorities nationwide.

Ganesh Thakurمشاهده پروفایل

استاد

• Small Molecule Medicinal Chemistry
• Drug Discovery Methodologies
• Cannabinoid Receptor Modulation
• +۵ مورد دیگر

Dr. Ganesh Thakur is a Full Professor and Chair of the Department of Pharmaceutical Sciences at Northeastern University. He holds a PhD in Organic Chemistry from the Institute of Chemical Technology, Mumbai, and has held roles from Senior Scientist to tenured Professor since 2004. His research focuses on cannabinoid receptor modulation, nicotinic acetylcholine receptors, and AI-driven drug discovery. Education: PhD, Organic Chemistry, Institute of Chemical Technology (ICT), Mumbai, India MS, Chemistry, Indian Institute of Technology (IIT), Mumbai BS, Chemistry, University of Mumbai Research Interests: Dr. Thakur pioneers small molecule therapeutics targeting cannabinoid receptors (CB1/CB2), nicotinic receptors (α4β2, α7, α9), and GIRK channels. His work addresses epilepsy, glaucoma, neurodegeneration, neuropathic pain, and substance use disorders. He has developed novel allosteric modulators with preclinical efficacy in pain, addiction, and neuroprotection. Grants: Active grants include NIH/NIGMS (Targeting α7 nAChR), Canadian Institutes of Health Research (CB1 PAMs for infantile spasms), and NIH/NHLBI (GIRK channel regulation). Awards: Recipient of 2023 Distinguished Mentor Award, Hind Rattan Award, and multiple RISE Awards for student mentorship. Notable honors include the 2018 Best Patent Award (US Patent #9,926,275 B2) and NIDA Early Career Award (2009). Labs/Teams: Leads the Cannabinoid and Nicotinic Receptor Research Group at Northeastern's Center for Drug Discovery, focusing on translational drug development for CNS disorders.

Andrew Kimمشاهده پروفایل

استادیار

• Behavioural addictions
• Substance use disorders
• Concurrent disorders
• +۳ مورد دیگر

Dr. Andrew Kim is an Assistant Professor in the Department of Psychology at Toronto Metropolitan University and an Adjunct Scientist at the University of Ottawa Institute of Mental Health Research. He specializes in behavioral addictions, substance use disorders, and concurrent mental health conditions. PhD in Clinical Psychology from the University of Calgary CPA-accredited psychology residency at The Royal Ottawa Mental Health Centre His research focuses on identifying shared psychological risk factors (e.g., emotion dysregulation, impulsivity) across substance and behavioral addictions to develop integrated treatments. He leads the Addictions and Mental Health (ADMH) Laboratory, collaborating with institutions in Canada, Australia, and Brazil. Key research themes include: Determinants of in-play sports betting behaviors Links between childhood trauma and cannabis use Concurrent disorders in gambling and substance use Psychotic-like experiences in cannabis users His work is funded by the Social Sciences and Humanities Research Council of Canada, Gambling Research Exchange Ontario, and the American Psychological Association’s Society of Addiction Psychology. Notable awards include the Banting Post-Doctoral Fellowship (declined) and Killam Trusts Fellowship. Dr. Kim’s lab investigates treatment development for comorbid addictions and mental health conditions using surveys, interviews, and ecological assessments. He actively seeks diverse researchers for his team.

Kent Kiehlمشاهده پروفایل

استاد

• Psychopathy
• Neuroscience
• Cognitive Neuroscience
• +۴ مورد دیگر

Kent Kiehl is a Professor of Psychology and Neuroscience at the University of New Mexico, affiliated with the Mind Research Network. His research focuses on psychopathy, neuroimaging, and legal applications of neuroscience. He leads the world's largest database of brain data from incarcerated populations using mobile MRI units, studying mental health issues like psychopathy, substance abuse, and externalizing disorders. Education: Ph.D., University of British Columbia (2000). He trains clinicians in neuroimaging techniques and consults on legal cases involving neuroscience. His lab collaborates with correctional facilities and institutions like the University of Wisconsin-Madison and the Mendota Juvenile Treatment Center. Research Interests: Psychopathy assessment (Hare PCl-R), neuroscience of criminal behavior, neurolaw, and cetacean cognition. He emphasizes predicting recidivism and treatment outcomes through brain structure/function analysis. His work bridges neuroscience with legal systems, informing interventions and prevention strategies. Key Projects: Brain Safe program for athlete concussion assessment, mobile fMRI deployment in prisons, and the Mendota Juvenile Treatment Center's decompression model. His lab includes postdoctoral fellows, graduate students, and collaborators like Vince Calhoun and Michael Koenigs. Public Engagement: Authored The Psychopath Whisperer , appeared on Megyn Kelly TODAY, and been featured in media outlets discussing psychopathy, criminal behavior, and neuroscience in law. He advocates for neuroscience-informed legal policies and public understanding of mental health.

Rainer Spanagelمشاهده پروفایل

استاد

• Addiction Research
• Neuropharmacology
• Translational Medicine
• +۶ مورد دیگر

Prof. Dr. Rainer Spanagel serves as the Head of the Institute of Psychopharmacology at the Central Institute of Mental Health (ZI) within the Medical Faculty Mannheim of Heidelberg University. His research focuses on addiction neuroscience, particularly alcohol and drug dependence, with a strong emphasis on translational approaches bridging preclinical and clinical research. Key areas include comorbid psychiatric disorders (anxiety, depression, ADHD), neurobiological mechanisms of relapse, and the development of novel therapeutic interventions. Spanagel's work utilizes advanced methodologies such as transgenic animal models, neuroimaging (MRI/fMRI), and systems medicine approaches. He leads projects on epigenetic modulation (e.g., oxytocin in alcohol addiction), drug repurposing (psilocybin), and the impact of adverse childhood experiences on addictive behaviors. Major grants include EU NEURON, BMBF (AERIAL, Target-OXY), and DFG funding for systems medicine and single-cell sequencing studies. His research integrates genetic, environmental, and neurochemical factors to address addiction's biological underpinnings. Notable contributions include identifying hyperdopaminergic states in alcohol abstinence and the role of RasGRF2 in cocaine reward pathways. Current initiatives focus on precision medicine strategies for substance use disorders through multi-omics integration and behavioral monitoring. Key Research Themes: Translational addiction, neuropharmacology, comorbidity mechanisms, epigenetics. Collaborations: Pharmaceutical industry partnerships for preclinical drug trials, multi-institutional consortia (SysMedSUDs, TRR265). Facilities: 9.4T MRI for animal neuroimaging, in silico brain banks integrating single-cell omics data.